UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors

Oncogene, 2020-11, Vol.39 (45), p.6935-6949

2020

Volltextzugriff (PDF)

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

The Journal of clinical investigation, 2022-12, Vol.132 (23)

2022

Volltextzugriff (PDF)

Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer

The Prostate, 2023-11, Vol.83 (15), p.1470-1493

2023

Volltextzugriff (PDF)

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/[beta]-catenin/TCF-4 complex inhibition of c-MYC transcription

The Prostate, 2014-08, Vol.74 (11), p.1118

2014

Volltextzugriff (PDF)

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription

The Prostate, 2014-08, Vol.74 (11), p.1118-1131

2014

Volltextzugriff (PDF)

Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer

Molecular cancer therapeutics, 2020-11, Vol.19 (11), p.2353-2362

2020

Volltextzugriff (PDF)

Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer

The Prostate, 2012-10, Vol.72 (14), p.1491-1505

2012

Volltextzugriff (PDF)

The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells

Cancer research (Chicago, Ill.), 2008-12, Vol.68 (23), p.9703-9711

2008

Volltextzugriff (PDF)

Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment

Cancer research (Chicago, Ill.), 2013-02, Vol.73 (4), p.1386-1399

2013

Volltextzugriff (PDF)

Of mice and men-warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively

The Prostate, 2013-09, Vol.73 (12), p.1316-1325

2013

Volltextzugriff (PDF)

Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models

The Prostate, 2024-07, Vol.84 (10), p.909-921

2024

Volltextzugriff (PDF)

Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling

PloS one, 2010-07, Vol.5 (7), p.e11475

2010

Volltextzugriff (PDF)

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

Science translational medicine, 2012-06, Vol.4 (140), p.140ra86

2012

Volltextzugriff (PDF)

Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells

Cancer research (Chicago, Ill.), 2006-09, Vol.66 (17), p.8598-8607

2006

Volltextzugriff (PDF)

Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors

Oncogene, 2021-06, Vol.40 (22), p.3914-3916

2021

Volltextzugriff (PDF)

Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors

Oncogene, 2021-03, Vol.40 (11), p.2148-2148

2021

Volltextzugriff (PDF)

Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers

Clinical cancer research, 2006-07, Vol.12 (13), p.4072-4079

2006

Volltextzugriff (PDF)

Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay

Oncotarget, 2016-11, Vol.7 (44), p.71298-71308

2016

Volltextzugriff (PDF)

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

The Prostate, 2012-05, Vol.72 (6), p.638-648

2012

Volltextzugriff (PDF)

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

The Prostate, 2007-05, Vol.67 (7), p.790-797

2007

Volltextzugriff (PDF)

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

The Prostate, 2006-12, Vol.66 (16), p.1768-1778

2006

Volltextzugriff (PDF)

Androgen Receptor as a Licensing Factor for DNA Replication in Androgen-Sensitive Prostate Cancer Cells

Proceedings of the National Academy of Sciences - PNAS, 2006-10, Vol.103 (41), p.15085-15090

2006

Volltextzugriff (PDF)

PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor

The Prostate, 2006-09, Vol.66 (12), p.1329-1338

2006

Volltextzugriff (PDF)

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

Oncotarget, 2014-09, Vol.5 (18), p.8093-8106

2014

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(86)

Publikationsform

Sprache

Englisch
(92)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/[beta]-catenin/TCF-4 complex inhibition of c-MYC transcription

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription

Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer

Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer

The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells

Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment

Of mice and men-warning: Intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively

Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models

Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells

Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors

Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer

Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers

Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

Androgen Receptor as a Licensing Factor for DNA Replication in Androgen-Sensitive Prostate Cancer Cells

PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

Suchergebnisse filtern